Free Trial

Ensysce Biosciences (ENSC) Competitors

Ensysce Biosciences logo
$2.07 0.00 (0.00%)
As of 03:22 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ENSC vs. BCAB, ADAP, MBRX, CASI, QTTB, FNCH, PASG, RVPH, RLMD, and PMN

Should you be buying Ensysce Biosciences stock or one of its competitors? The main competitors of Ensysce Biosciences include BioAtla (BCAB), Adaptimmune Therapeutics (ADAP), Moleculin Biotech (MBRX), CASI Pharmaceuticals (CASI), Q32 Bio (QTTB), Finch Therapeutics Group (FNCH), Passage Bio (PASG), Reviva Pharmaceuticals (RVPH), Relmada Therapeutics (RLMD), and Promis Neurosciences (PMN). These companies are all part of the "pharmaceutical products" industry.

Ensysce Biosciences vs. Its Competitors

BioAtla (NASDAQ:BCAB) and Ensysce Biosciences (NASDAQ:ENSC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation, media sentiment and analyst recommendations.

BioAtla has a net margin of 0.00% compared to Ensysce Biosciences' net margin of -88.76%. Ensysce Biosciences' return on equity of -167.23% beat BioAtla's return on equity.

Company Net Margins Return on Equity Return on Assets
BioAtlaN/A -1,177.18% -137.51%
Ensysce Biosciences -88.76%-167.23%-104.59%

Ensysce Biosciences has lower revenue, but higher earnings than BioAtla. Ensysce Biosciences is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioAtla$11M1.92-$69.78M-$1.10-0.33
Ensysce Biosciences$5.21M1.18-$7.99M-$4.03-0.51

BioAtla has a beta of 0.9, suggesting that its stock price is 10% less volatile than the S&P 500. Comparatively, Ensysce Biosciences has a beta of 1, suggesting that its stock price has a similar volatility profile to the S&P 500.

In the previous week, Ensysce Biosciences had 2 more articles in the media than BioAtla. MarketBeat recorded 4 mentions for Ensysce Biosciences and 2 mentions for BioAtla. BioAtla's average media sentiment score of -0.37 beat Ensysce Biosciences' score of -0.47 indicating that BioAtla is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BioAtla
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Ensysce Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

77.2% of BioAtla shares are owned by institutional investors. Comparatively, 5.6% of Ensysce Biosciences shares are owned by institutional investors. 11.2% of BioAtla shares are owned by company insiders. Comparatively, 7.9% of Ensysce Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

BioAtla currently has a consensus target price of $5.00, indicating a potential upside of 1,292.76%. Given BioAtla's stronger consensus rating and higher probable upside, research analysts plainly believe BioAtla is more favorable than Ensysce Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioAtla
0 Sell rating(s)
3 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Ensysce Biosciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

BioAtla beats Ensysce Biosciences on 10 of the 15 factors compared between the two stocks.

Get Ensysce Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for ENSC and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENSC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ENSC vs. The Competition

MetricEnsysce BiosciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$6.15M$3.09B$5.82B$9.75B
Dividend YieldN/A2.23%3.84%4.09%
P/E Ratio-0.5121.0131.1425.96
Price / Sales1.18396.98475.48122.90
Price / CashN/A43.0937.1558.38
Price / Book2.018.069.116.38
Net Income-$7.99M-$54.72M$3.26B$265.56M
7 Day Performance0.98%2.30%1.94%1.81%
1 Month Performance-5.91%7.21%4.91%1.14%
1 Year Performance-66.34%12.85%31.21%20.98%

Ensysce Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ENSC
Ensysce Biosciences
0.4093 of 5 stars
$2.07
flat
N/A-66.4%$6.15M$5.21M-0.5110
BCAB
BioAtla
2.3276 of 5 stars
$0.36
+2.8%
$5.00
+1,279.3%
-81.1%$20.60M$11M-0.3360Gap Up
ADAP
Adaptimmune Therapeutics
2.1315 of 5 stars
$0.09
+10.7%
$1.35
+1,475.4%
-95.1%$20.54M$178.03M-0.32490Insider Trade
Gap Up
MBRX
Moleculin Biotech
2.9185 of 5 stars
$0.62
-7.8%
$4.00
+543.1%
-76.6%$20.38MN/A0.0020
CASI
CASI Pharmaceuticals
3.6938 of 5 stars
$1.73
+6.1%
$4.00
+131.2%
-62.0%$20.05M$28.54M-0.68180
QTTB
Q32 Bio
2.6359 of 5 stars
$1.79
+9.8%
$12.17
+579.7%
-95.2%$19.88M$1.16M-0.4239News Coverage
Short Interest ↓
FNCH
Finch Therapeutics Group
N/A$12.24
-1.6%
N/A+22.1%$19.66MN/A-1.39190
PASG
Passage Bio
3.9041 of 5 stars
$5.90
-5.9%
$150.00
+2,442.4%
-50.5%$19.56MN/A-0.29130
RVPH
Reviva Pharmaceuticals
2.7469 of 5 stars
$0.45
+9.9%
$9.00
+1,911.2%
-38.7%$19.54MN/A-0.575Analyst Revision
RLMD
Relmada Therapeutics
4.3051 of 5 stars
$0.56
-4.1%
$5.00
+787.9%
-78.2%$19.50MN/A-0.2510
PMN
Promis Neurosciences
3.0681 of 5 stars
$0.63
+11.3%
$4.33
+590.0%
-55.4%$18.44MN/A-12.565Positive News

Related Companies and Tools


This page (NASDAQ:ENSC) was last updated on 8/22/2025 by MarketBeat.com Staff
From Our Partners